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alent. Thus, the structure closely parallels human skin. In 
consequence, the Phenion FT model appears to be suitable 
for percutaneous absorption studies in hazard analysis and 
should be subjected to a catch-up validation study. 
 Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Percutaneous absorption studies are essential for haz-
ard analysis of compounds making contact with the skin 
surface as well as in the development of drugs for dermal 
or transdermal application. In order to standardise the 
predictive testing of chemical compounds and cosmetics 
for regulatory purposes, the Organisation for Economic 
Co-Operation and Development (OECD) adopted guide-
line 428  [1] and a corresponding technical guidance doc-
ument  [2] which describe methods for assessing absorp-
tion by using human and animal skin ex vivo. Excised 
human skin is preferable to animal skin (e.g. rat skin or 
pig skin), but it is clearly less available. To overcome this 
shortage, a protocol was developed and validated accord-
ing to the OECD principles  [3] by using three commer-
cially available types of reconstructed human epidermis 
(RHE). Permeability of the Epiderm  (Mattek Corp., 
Ashland, Mass., USA), SkinEthic  and EPISKIN  
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 Abstract 
 In recent years many efforts have been made to replace der-
mal toxicity testing of chemicals in the animal by in vitro as-
says. As a member of a German research consortium, we 
have previously contributed to the validation of an in vitro 
test protocol for percutaneous absorption studies on the ba-
sis of reconstructed human epidermis and both human and 
pig skin ex vivo. Aiming to assess the barrier properties of a 
newly developed reconstructed skin model, this protocol 
has now been transferred to the Phenion  Full-Thickness 
Skin Model (FT model). The permeation of testosterone and 
caffeine was quantified in parallel to that of pig skin using 
Franz-type diffusion cells. In addition, the permeation of 
benzoic acid and nicotine was studied. As expected, the FT 
model is more permeable than pig skin, yet its barrier prop-
erties are well in accordance with those of reconstructed hu-
man epidermis when compared to previous data. In fact, the 
FT model most efficiently retards testosterone as the com-
pound of highest lipophilicity, which can be explained by an 
additional uptake by a reservoir formed by the dermis equiv-
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(L’Oréal, Paris, France) models was compared to that of 
human epidermis, pig skin and bovine udder skin by us-
ing 9 compounds widely varying in physicochemical 
characteristics including the OECD standards testoster-
one, caffeine and benzoic acid. The results demonstrate 
that RHE can be used for skin penetration studies, taking 
product-specific overpredictability into account  [4, 5] . 
Moreover, in vitro skin corrosion testing based on RHE 
has been approved by the OECD (guideline 341  [6] ) and 
a retesting procedure for phototoxicity of compounds 
positive in the 3T3 fibroblast test yet of poor skin penetra-
tion has been adopted by the European Union (ECVAM 
Scientific Advisory Committee  [7] ). Recently, a method 
for skin irritation testing has also been validated  [8] , and 
is submitted to the ECVAM Scientific Advisory Commit-
tee for the scientific review process. This protocol has 
now been adapted for the development and validation of 
a stand-alone in vitro skin irritation test using the Epi-
derm model  [9] .
 Besides RHE reconstructed human full-thickness 
(FT) skin models, e.g. Epiderm FT and Phenion  Full-
Thickness Skin Model  [10, 11] , were introduced to the 
market. These consist of keratinocytes and fibroblasts 
and present an epidermis, a basement membrane and a 
dermis featuring morphology and tissue functionality 
very close to the characteristics of human skin. Both RHE 
and FT models have already been evaluated for the per-
meation and biotransformation of various compounds, 
e.g. of hair dye ingredients (N-acetylation  [12] ) and glu-
cocorticoids (ester hydrolysis  [13–15] ). As genotoxicity 
and sensitisation are often linked to biotransformation of 
the compound of interest within the skin, which can vary 
considerably between the major cell types forming the 
skin  [14, 16–18] , FT skin models may be superior to RHE 
for the prediction of biotransformation-linked toxic end-
points  [19, 20] . According to the outcome of first percu-
taneous absorption studies in the FT model  [15] , the val-
idated protocol for skin absorption studies in RHE has 
now been transferred for a characterization of the Phe-
nion Full-Thickness Skin Model (FT model) using a rel-
evant selection of test compounds.
 Materials and Methods 
 Experiments were performed close to the principles of good 
laboratory practice. The test procedures used are described in de-
tail by study-oriented programmes devised by the skin absorption 
study group (http://www.gd-online.de/german/fgruppen.htm  [4] ) 
and were adopted taking the handling instructions of the manu-
facturer of the FT model into account (www.phenion.com).
 Test Chemicals and Preparation of Solutions 
 For cutaneous absorption studies, the OECD proposes the use 
of caffeine (MW = 194; logP = 0.01) and testosterone (MW = 288; 
logP = 3.47) as reference compounds with a low or high lipophi-
licity, respectively. Moreover, the OECD standard compounds 
benzoic acid (MW = 122.1; logP = 1.90; logD pH 7.4 = –1.25) and 
nicotine (MW = 162.2; logP = 0.72; logD pH 7.4 = 0.02) are also in-
cluded in the panel of test compounds.
 Benzoic acid (65-85-0), caffeine (58-08-2), nicotine (54-11-5), 
testosterone (58-22-0), ethanol (64-17-54), Igepal  CA-630 [(octyl-
phenoxy)polyethoxyethanol, 9043-52-1] and phosphate-buffered 
saline, pH 7.4 (PBS), were supplied by Sigma-Aldrich (Munich, 
Germany). The radiolabelled compounds [7- 14 C]-benzoic acid (57 
mCi/mmol), 1-methyl- 14 C-caffeine (51.20 mCi/mmol),  L -(–)-N-
methyl- 3 H-nicotine (66.9 Ci/mmol) and 2,4,6,7- 3 H-testosterone 
(100 Ci/mmol; 6384-79-8) were purchased from Moravek Bio-
chemicals (Brea, Calif., USA), ARC Inc. (St. Louis, Mo., USA), 
Perkin Elmer Life Sciences (Boston, Mass., USA) and Amersham 
(Freiburg, Germany), respectively.
 Stock solutions of testosterone (40   g/ml) were prepared by 
dissolving 10 mg of the compound in 1.0 ml of ethanol. Then, 200 
  l of this ethanolic solution were added to 1.0 ml of Igepal CA-630 
and expanded to 50.0 ml with PBS. Stock solutions of benzoic 
acid, caffeine and nicotine (1,000   g/ml) were obtained by dis-
solving 50 mg of the compound in 50.0 ml of PBS. In order to 
prepare the solutions for permeation testing, stock solutions were 
spiked with an appropriate amount of the radiolabelled com-
pound to achieve a total radioactivity of 2   Ci/ml. Solutions 
stored at 4 ° C are stable for at least 4 weeks  [5] .
 Test Matrices 
 The Phenion FT model (Henkel, Düsseldorf, Germany) is a 
multilayered equivalent of the human skin. It has a diameter of 
1.3 cm and consists of keratinocytes and fibroblasts derived from 
the same human donor. The tissue pieces were handled according 
to the instructions of the manufacturer. Immediately after arriv-
ing each specimen of the FT model was transferred from the de-
livery plate into a 3.5-cm Petri dish equipped with filter paper and 
filled with approximately 4–5 ml of preheated culture medium 
(37 ° C, Air Liquid Interface Medium). Tissue pieces were then in-
cubated overnight at 37 ° C, with 5% CO 2 before being mounted 
into Franz-type diffusion cells or subjected to histological exam-
ination.
 Pig skin was obtained from 3 donor animals (breed ‘Deutsche 
Landrasse’, 43–45 kg, from 12 to 14 weeks old) without soaking 
the cadaver in boiling water from the Department of Comparative 
Medicine and Facilities of Experimental Animal Sciences, Chari-
té-Universitätsmedizin Berlin (Berlin, Germany). Immediately 
after stripping, the skin was placed in ice-cold cloth and trans-
ferred to the laboratory. There the skin was trimmed removing 
subcutaneous fat and connective tissue and then subjected to 
cryopreservation at –20 ° C for at least 1 day and up to a maximum 
of 6 months  [5] . On the day of the experiment, the pig skin was 
thawed and skin sheets of 1,000  8 100   m thickness were pre-
pared using a dermatome (Aesculap  GA 630, Aesculap, Tuttlin-
gen, Germany). After checking the skin thickness using a calliper 
(Pocket Thickness Gage, Mitutoyo Corp., Kawasaki, Japan), the 
skin was punched to obtain discs of 2 cm in diameter, rehydrated 
in PBS for 30 min and inspected for integrity before being mount-
ed into Franz-type diffusion cells.
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 Permeation Assay 
 The first experiments (in 2006) were performed with pig skin 
and the FT model applying testosterone and caffeine. In 2007 the 
FT model was retested for the permeation of caffeine and in ad-
dition for that of benzoic acid and nicotine.
 Using the static set-up and the infinite dose approach, perme-
ation tests (Franz-type diffusion cells, diameter 15 mm, volume 
12 ml; Permegear Inc., Bethlehem, Pa., USA) were performed in 
triplicate, with pig skin from 3 donors and with 3 batches of the 
skin model, respectively. Thus, with each compound a total of at 
least 9 experiments were performed for each matrix. Since the size 
of the FT model was too small (between 11 and 12 mm) to be di-
rectly mounted into the Franz-type diffusion cells, special inserts 
constructed for the Episkin model  [21] were used. The surface 
area was thereby reduced from 1.767 to 0.358 cm 2 . Both pig skin 
and skin model were mounted into Franz-type diffusion cells 
with the stratum corneum facing the air.
 Experiments were performed using PBS as receptor fluid (12 
 8 0.2 ml) which was maintained at 33.5  8 1 ° C and magneti-
cally stirred (500 rpm). The system was allowed to equilibrate for 
30 min before a sample of receptor fluid was collected. Subse-
quently, 500 and 110   l of spiked test compound solutions were 
applied to the pig skin and the FT model, respectively, resulting 
in an identical dose of 284.1   g/cm 2 of caffeine, benzoic acid or 
nicotine and 11.3   g/cm 2 of testosterone. Then the donor com-
partment of Franz-type diffusion cells was covered by Nesco-
film  (Carl Roth, Karlsruhe, Germany) for 26 h to avoid donor 
fluid evaporation. Receptor fluid was sampled repeatedly for up 
to 26 h and each time replaced by fresh PBS. Samples were imme-
diately stored at –20 ° C until analysis by scintillation counting.
 Tissues were discarded if there was a wet skin surface caused 
by the appearance of receptor fluid during the equilibration 
phase. Moreover, tissue integrity as well as the avoidance of air 
bubbles was monitored throughout the experiment.
 Liquid Scintillation Counting 
 Amounts of the test compounds in the receptor fluid were 
quantified using radiochemical detection (Microbeta Plus, Wal-
lac, Turku, Finland) as described  [5, 22] .
 Morphology Investigation of the Skin Model 
 In order to prove skin model conformity to the standards de-
fined by OECD guideline 431  [6] and to investigate stress effects 
due to the experimental conditions, 7 specimens of each batch 
were also subjected to histology. One specimen was inspected as 
received. The others were mounted into Franz-type diffusion cells 
and exposed to 110   l of the PBS vehicle or caffeine and testoster-
one solution for 8 and 26 h, respectively (1 specimen each). Then 
punch biopsies of 8 mm in diameter were taken from the centre of 
the tissue (treated area), fixed in 2 ml Karnovsky solution  [23] and 
stored at +4 ° C. After several washing steps and a gradual dehydra-
tion procedure, the samples were embedded into epoxy resin  [24] , 
cut into 1- to 2-  m semi-thin sections, stained with 1% toluidine 
(108-44-1)/1% pyronine G (92-32-0) and then evaluated under 
blind conditions. A scoring system with up to 8 points ( table 1 ) 
defined the degree of damage, which is an extension of the scoring 
system set-up for morphological analysis of reconstructed human 
epidermis exposed to the donor vehicles  [22] . Moreover, the num-
ber of keratinocyte layers building up the epidermis of the FT 
model was derived from the histology of untreated specimens.
 Data Evaluation and Statistics 
 For each individual experiment, cumulative amounts of the 
permeated compounds in the receptor medium were plotted ver-
sus time (means  8 standard deviation, SD). The apparent perme-
ability coefficient P app (equation 1) and lag time were calculated 
from a regression line based on mean values of the experiment 
 [25, 26] assuming a constant tissue thickness and diffusion area 
resulting in an equation only consisting of the slope of the linear 
portion of the permeation curve divided by the applied donor 
concentration.
 Equation 1: P app = (V/A  C i )  (dC a /dt)
 where P app = apparent permeability coefficient (cm/s), V = volume 
of the receiver chamber (12 cm 3 ), A = area of the skin surface ex-
posed to the donor medium (1.767 or 0.358 cm 2 ), C i = initial con-
centration of the applied substance (  g/cm 3 ) and dC a /dt = in-
creasing concentration of the substance in the receptor fluid with 
increasing time.
 Using the published algorithm and spread sheets  [27] , P app and 
lag time were calculated conforming to the standards of the vali-
dation study  [4] which requires at least 6 data points in the linear 
range. If 6 valid data points were not available, P app was estimated 
by approximating a linear increase in the permeation curve with-
in the first 4 h (5 data points).
 Results are presented as the arithmetic mean value, SD and 
coefficient of variation (%). Differences in skin permeation were 
evaluated by the Wilcoxon test; p  ^  0.05 was regarded to indicate 
a statistically significant difference.
Table 1. Score system used to define the degree of damage of the 
FT model
8 = Normal – Normal morphology
7 = Normal to
mild damage
– From normal morphology to mild
damage
6 = Mild damage –
–
–
Mild irritation
Hyperkeratosis of the stratum corneum
Oedema of the viable cells
5 = Mild to
moderate damage
– From mild to moderate damage
4 = Moderate
damage
–
–
–
Irritation
Appearance of intra- and intercellular 
vacuoles in viable keratinocytes
Partial loss of corneocytes
3 = Moderate to
severe damage
– From moderate to severe damage
2 = Severe
damage
–
–
–
–
Severe irritation
Presence of many intra- and intercellular 
vacuoles in viable keratinocytes
Massive loss of corneocytes
Detachment of the viable keratinocytes
from the underlying dermis-like structure
1 = Keratinisation – Keratinisation of the upper skin layers
 Ackermann /Lombardi Borgia /Korting /
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 Results 
 Permeation Tests 
 The first experiments with the Phenion FT model (3 
batches) were based on testosterone and caffeine which 
are OECD standard compounds for high and low lipo-
philicity. The permeability of the FT model was com-
pared to that of pig skin ( fig. 1 ). To study the reproduc-
ibility of the barrier over time, another 3 batches of the 
model produced 1 year later were subjected to another 
testing series using caffeine but also benzoic acid and nic-
otine ( fig. 2 ). Thus, results of caffeine retesting should in-
dicate batch-related overpredictability over time.
 With pig skin the maximum concentration of caffeine 
and testosterone attained in the receptor fluid was always 
lower than the permitted range of 10% saturation solubil-
ity described previously  [28] . Results conform to the in-
finite dose approach, and permeation profiles are ap-
proximated to be linear up to 26 h ( fig. 1 ). At this time 1.4 
 8 0.3% of the applied caffeine and 3.1  8 1.3% of testos-
terone had permeated into the receiving compartment. 
With the FT model, however, testosterone results did not 
conform to the infinite dose approach over time, since 
the limit of the 10% saturation solubility was already at-
tained at 8 h (22.6% after 26 h) indicating restricted dif-
fusion in the long time range ( fig. 1 ). In contrast, the 
maximum concentration of benzoic acid, caffeine and 
nicotine attained in the receptor fluid was always lower 
than the permitted range of 10% saturation solubility 
 [28] . Efficient permeation of the FT model resulted in a 
depletion of the test compounds in the donor compart-
ment ( fig. 1 ,  2 ). In fact, 95.7  8 8.7% (first series) or 95.2 
 8 4.5% (second series) of the applied caffeine, respec-
tively, 91.0  8 6.0% of the applied benzoic acid, 70.4  8 
4.3% of the applied nicotine and 39.4  8 2.9% of the ap-
plied testosterone were recovered in the receptor fluid at 
the end of the experiment (26 h). To avoid depletion-re-
lated error, P app values and lag time had to be derived 
from amounts permeated within 6 h (caffeine, benzoic 
acid, nicotine) and 8 h (testosterone). The respective data 
indicate a linear increase in the amount of the agent in 
the receptor fluid with time despite the still rather high 
fraction of permeated compound. Once more, interbatch 
variability was low.
 As expected with the FT model, the lag times ( table 2 ) 
were clearly lower than with pig skin. With the latter, lag 
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 Fig. 1. Cumulative permeation (mean values  8 SD) of the FT model and pig skin by the test compounds. Ex-
periments were performed in reconstructed skin of 3 batches and pig skin from 3 donor animals in triplicate. 
 a Testosterone.  b Caffeine. 
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times of all test compounds were well in accordance with 
those reported previously  [4] . Except for testosterone, lag 
times of the FT model were shorter than lag times ob-
served previously with the EPISKIN model (caffeine
0.81 h, benzoic acid and nicotine 0.62 h  [4] ) which can be 
explained by the structure of the reconstructed tissues: 
the dermis of the FT model is built up from a bioartificial 
scaffold which contains fibroblasts embedded into loose-
ly packed newly synthesized ECM fibres. In contrast the 
EPISKIN keratinocytes are grown on a densely packed 
collagen layer. Thus, the lag times of the FT model under-
shoot those of the RHE model. Even shorter were lag 
times observed with the Epiderm and SkinEthic recon-
structed human epidermis ( ! 0.35 h) which are built up 
from keratinocytes grown on a synthetic supporting 
membrane  [4] .
 In accordance with the results of the RHE validation 
study, too, the P app value of testosterone calculated for the 
FT model ( table 2 ) is one order of magnitude higher than 
the P app value found with pig skin but is in the same range 
as P app values found with RHE (2.10  8 0.46 to 5.70  8 1.51 
 ! 10 –6 cm/s  [4] ). This conforms to an additional reser-
voir formed by the dermis or dermis equivalent in the FT 
model, respectively  [29] . Retesting caffeine, the P app value 
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 Fig. 2. Cumulative permeation (mean values  8 SD) of the FT model by the test compounds. Each compound 
was tested in 3 batches (3 different symbols) in triplicate.  a Benzoic acid.  b Caffeine.  c Nicotine. 
Skin matrix Permeation 6 h Papp
!10–6 cm/s
CV
%
Lag time
h
g/cm2 %
Testosterone
Pig skin 0.0880.06 0.0380.02 0.0880.02 25.0 5.6083.28
FT model 1.2580.18 10.981.60 1.5880.26 16.5 0.5680.11
Caffeine
Pig skin 0.2480.26 0.0880.09 0.0380.01 33.3 6.7382.44
FT model (1) 131.484.03 46.081.40 6.7080.14 2.08 0.5580.18
FT model (2) 140.9823.5 49.688.3 6.7380.33 9.68 0.4380.09
Benzoic acid
FT model 127.186.14 44.882.16 6.9380.39 5.63 0.2880.04
Nicotine
FT model 131.5818.5 46.386.52 6.5880.50 7.60 –0.0380.02
CV = Coefficient of variation.
Table 2. Papp values, lag time and drug 
permeated into the receptor fluid 
following 0.1% solution of benzoic acid, 
caffeine and nicotine and 0.004% 
testosterone/2% Igepal applied to pig skin 
and the FT model (mean values 8 SD)
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did not deviate significantly from the one of the first se-
ries, which appears to indicate a consistent development 
of barrier properties of the FT model over a production 
period of 1 year. The P app values of benzoic acid, caffeine 
and nicotine were rather close ( table 2 ), which holds true 
for RHE only with benzoic acid and caffeine, with nico-
tine being more permeable. The P app values of benzoic 
acid and caffeine calculated for the FT model slightly ex-
ceeded the P app values found with reconstructed human 
epidermis but were close for nicotine. As with RHE  [4] , 
the FT model surmounted by one order of magnitude the 
permeability of pig skin. Interestingly, the coefficients of 
variation of P app values generated for the FT model ( ta-
ble 2 ) are less than with pig skin  [4] and RHE. However, 
it should be noted that the data reported here were gener-
ated by a single laboratory, while previous data were ob-
tained by a joint group.
 Morphology 
 Morphology of the FT model was investigated study-
ing vertical sections of models subjected to light micros-
copy. As received, the FT model presented an overall nor-
mal tissue architecture and morphology (score 8.0,  ta-
ble 1 ,  fig. 3 ) which confirms the model claims. The average 
number of viable epidermal cell layers was 8.3  8 0.6, with 
the thickness of viable epidermis and stratum corneum 
being 9.0  8 1.7 and 4.5  8 3.3   m, respectively.
 The histological score describing the degree of dam-
age undergone by the FT model when subjected to per-
meation testing is reported in  table 3 , histological pic-
tures of the models are shown in  figure 3 . After 8 h the 
damage induced was clearly dependent on the donor flu-
id. Specimens treated with PBS (not shown) or caffeine/
PBS showed only mild to moderate damage ranging from 
normal morphology to oedema of the viable cells. Some 
tissues presented also intra- and intercellular vacuoles 
and the beginning of the detachment of keratinocytes 
from the underlying dermis. Well in accordance with the 
previous experience obtained with RHE  [22] , severe dam-
Table 3. Histological score describing the damage undergone by 
the FT model subjected to permeation testing (mean values 8 SD; 
n = 3)
Donor medium 8 h 26 h
PBS 481 381
(moderate) (from moderate to severe)
Caffeine/PBS 682 381
(mild) (from moderate to severe)
Testosterone/PBS 281 382
+ 2% Igepal CA-630 (severe) (from moderate to severe)
a b c
 Fig. 3. Histological appearance of the FT model (toluidine/pyronine staining). Specimens of an identical batch 
were examined as received ( a ) and treated for 8 h with 0.1% caffeine/PBS ( b ) and 0.004% testosterone/PBS + 2% 
Igepal CA-630 ( c ), respectively. 
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age was seen in the specimens treated with 2% Igepal CA-
630 donor fluid, which can be derived from the presence 
of intra- and intercellular vacuoles, massive loss of cor-
neocytes and detachment of multiple keratinocytes from 
the underlying dermis. After 26 h, all specimens present-
ed moderate to severe damage.
 Discussion 
 Aiming to investigate the barrier properties of a new 
FT human skin model, the permeation of 4 standard 
compounds was studied. Taken together, the Phenion FT 
model appears to have a slightly weaker barrier against 
benzoic acid and caffeine than the previously tested RHE 
models  [4] , whereas the FT model more efficiently retards 
the permeation of lipophilic compounds such as nicotine 
and in particular testosterone ( table 2 ). A detailed com-
parison of the reconstructed tissues is given by  table 4 
which relates the P app values obtained using the FT mod-
el and those gained with RHE in the validation study  [4] 
to P app values obtained with pig skin  [4] . The comparison 
demonstrates that the barrier properties of the FT model 
appear to increase with lipophilicity of the test com-
pounds while they appear to decrease with the EPISKIN 
and SkinEthic models taking pH-related lipophilicity 
(logD) into account. As already stated, this conforms to 
an additional reservoir or physical barrier formed by the 
dermis equivalent, respectively, in particular if built up 
from dense material. Interestingly, the same was observed 
with bovine udder skin when compared to human and 
pig skin  [5] . With bovine udder skin the increase in per-
meability of hydrophilic compounds was explained by a 
less lipophilic lipid pattern. These findings suggest that 
the FT model might also contain a lipid pattern which 
differs from the pattern of human epidermis and RHE 
models used for the validation study.
 The experimental set-up in Franz-type diffusion cells 
obviously damaged the structure of the FT model; the 
degree of damage ( fig. 3 ,  table 3 ) was dependent on the 
donor medium and the time of exposure. The severest 
changes were seen with the admixture of Igepal CA-630, 
which is also well in accordance with alterations seen 
with reconstructed human epidermis. An even more dra-
matic effect with the testing of RHE was seen when Igepal 
CA-630 was added to the receptor fluid  [22] , thus making 
contact with viable keratinocytes. While these effects do 
not seem to impair the barrier properties in the relevant 
time frame, this should be different with respect to skin 
biotransformation, as can be derived from impaired glu-
cocorticoid ester cleavage observed previously  [30] . 
Therefore, the composition of donor and receptor fluid 
has to be selected with great care when studying biotrans-
formation or biotransformation-related endpoints such 
as skin genotoxicity and sensitisation. Relevant metabo-
lite formation in human skin ex vivo was observed for 
example with steroids  [16] and retinoids  [31] .
 Conclusions 
 The barrier of the Phenion FT model was found to be 
weaker than the barrier of pig skin, yet close to the bar-
rier of RHE. Since data reproducibility was good, the FT 
model appears to be suitable for percutaneous absorption 
studies of compounds in hazard analysis. Given the same 
result is also obtained by another independent laborato-
ry, the model should be subjected to a catch-up validation 
study within a joint project to quantify reproducibility 
and (over-)predictability based on a relevant number of 
compounds.
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Table 4. Ratio of Papp values obtained with the FT model and
RHE models over Papp values obtained with pig skin (data from 
Schäfer-Korting et al. [4])
Papp ratio in relation to pig skin
benzoic acid caffeine nicotine testosterone
logDpH 7.4 –1.25 0.01 0.02 3.47
FT model 24.8 21.6/21.7 8.23 6.32
Epiderm 13.0 1.90 6.06 11.1
SkinEthic 17.8 13.9 22.9 22.8
EPISKIN 3.57 9.48 8.25 8.40
 Ackermann /Lombardi Borgia /Korting /
Mewes /Schäfer-Korting 
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